Federal health regulators are asking tough questions about the risk of tumors and heart problems with an experimental diet pill from Arena Pharmaceuticals, which was previously rejected for similar safety concerns. The Food and Drug Administration denied approval for Arena’s lorcaserin in 2010 after scientists raised concerns about tumors that developed in animals studied with […]

This content is only available to members of the CSBJ.

To gain access, you’ll need to sign in or purchase Membership – Premium, Monthly, Membership – Premium, Yearly, Membership – Home Delivery Premium, Yearly or Corporate Membership

If you’re already a member, sign in here.

LEAVE A REPLY

Please enter your comment!
Please enter your name here